Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Phuong Dang
Institution:
South Australian Health and Medical Research Institute
Observed institutions:
South Australia Pathology,
Peter MacCallum Cancer Centre,
Novartis (Australia),
South Australian Health and Medical Research Institute,
Centre for Cancer Biology,
Hanson Institute,
Novartis Institutes for BioMedical Research,
The University of Adelaide
show all 8
ORCID:
0009-0007-3232-6397
Observed ORCID:
0009-0007-3232-6397
OpenAlex ID:
A5114160050
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
2013
·
David M. Ross
, Susan Branford
, et al.
·
Blood
·
770
OCT-1–mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib
2006
·
Deborah L. White
, Verity A. Saunders
, et al.
·
Blood
·
476
Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity
2007
·
Deborah L. White
, Verity A. Saunders
, et al.
·
Blood
·
365
Dasatinib Cellular Uptake and Efflux in Chronic Myeloid Leukemia Cells: Therapeutic Implications
2008
·
Devendra K. Hiwase
, Verity Saunders
, et al.
·
Clinical Cancer Research
·
228
Functional Activity of the OCT-1 Protein Is Predictive of Long-Term Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib
2010
·
Deborah L. White
, Phuong Dang
, et al.
·
Journal of Clinical Oncology
·
204
Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells
2018
·
on behalf of the Australasian Leukaemia and Lymphoma Group (ALLG)
, David M. Ross
, et al.
·
Leukemia
·
88
High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment
2017
·
Susan L. Heatley
, Teresa Sadras
, et al.
·
Haematologica
·
65
Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission
2019
·
Ilaria S. Pagani
, Phuong Dang
, et al.
·
Leukemia
·
55
Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib
2019
·
Chung H. Kok
, David T. Yeung
, et al.
·
Blood Advances
·
43
PDF
BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia
2018
·
Ilaria S. Pagani
, Phuong Dang
, et al.
·
Haematologica
·
41
PDF
ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cells
2018
·
Laura N. Eadie
, Phuong Dang
, et al.
·
PLoS ONE
·
29
PDF
Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions
2017
·
Teresa Sadras
, Susan L. Heatley
, et al.
·
Cancer Letters
·
26
CML Patients with Low OCT-1 Activity Achieve Better Molecular Responses on High Dose Imatinib Than on Standard Dose. Those with High OCT-1 Activity Have Excellent Responses on Either Dose: A TOPS Correlative Study
2008
·
Deborah L White
, Verity A Saunders
, et al.
·
Blood
·
19
Lineage-specific detection of residual disease predicts relapse in patients with chronic myeloid leukemia stopping therapy
2023
·
Ilaria S. Pagani
, Naranie Shanmuganathan
, et al.
·
Blood
·
17
PDF
Increased peroxisome proliferator-activated receptor γ activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cells
2017
·
Jueqiong Wang
, Liu Lu
, et al.
·
Haematologica
·
15
Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia
2019
·
David M. Ross
, Ilaria S. Pagani
, et al.
·
British Journal of Haematology
·
13
PDF
Clinical utility of genomic DNA Q-PCR for the monitoring of a patient with atypical e19a2 BCR-ABL1 transcripts in chronic myeloid leukemia
2020
·
Ilaria S. Pagani
, Phuong Dang
, et al.
·
Leukemia & lymphoma/Leukemia and lymphoma
·
10
Highly sensitive droplet digital polymerase chain reaction for BCR :: ABL1 messenger RNA identifies patients with chronic myeloid leukaemia with a low probability of achieving treatment‐free remission
2022
·
Liu Lu
, Chung Hoow Kok
, et al.
·
British Journal of Haematology
·
9
In Contrast to Imatinib, OCT-1 Mediated Influx Has Minimal Impact on Cellular Uptake of Dasatinib in CML Patients at Diagnosis.
2007
·
Devendra K. Hiwase
, Deborah L. White
, et al.
·
Blood
·
6
ABCB1 Overexpression May Predispose Imatinib Treated CML Patients to the Development of Abl Kinase Domain Mutations, and May Be an Important Contributor to Acquired Resistance.
2006
·
Deborah White
, Phuong Dang
, et al.
·
Blood
·
6
Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib
2023
·
Chung H. Kok
, Verity A. Saunders
, et al.
·
Blood Cancer Journal
·
5
PDF
The Functional Activity of the OCT-1 Protein Is Predictive of Molecular Response and Survival in CP-CML Patients Treated with Imatinib: A 5 Year Update of the TIDEL Trial.
2009
·
Deborah L White
, Verity A Saunders
, et al.
·
Blood
·
5
Increased Inflammatory Cytokines in Plasma Are Associated with Sustained Treatment-Free Remission in Chronic Myeloid Leukaemia
2024
·
Chung Hoow Kok
, Verity A Saunders
, et al.
·
Blood
·
4
High Prevalence of Relapse in Australian Children with Ph-like Acute Lymphoblastic Leukemia Despite Risk Adapted Treatment
2015
·
Susan L Heatley
, Teresa Sadras
, et al.
·
Blood
·
3
CD302 predicts achievement of deep molecular response in patients with chronic myeloid leukemia treated with imatinib
2024
·
Chung Hoow Kok
, Yazad Irani
, et al.
·
Blood Neoplasia
·
2
Show more works
View as search
Works count:
37
Citation count:
2,514
H-index:
15
I10-index:
17
Year
Topic
Type